InflaRx
IFRX
26 hedge funds and large institutions have $19.2M invested in InflaRx in 2020 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 3 increasing their positions, 10 reducing their positions, and 6 closing their positions.
100% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 6
30% more funds holding
Funds holding: 20 → 26 (+6)
1.04% less ownership
Funds ownership: 20.26% → 19.22% (-1%)
9% less capital invested
Capital invested by funds: $20.9M → $19.2M (-$1.78M)
70% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$3.95M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$1.65M |
| 3 |
BC
Birchview Capital
Burlington,
Vermont
|
+$407K |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$396K |
| 5 |
Walleye Capital
New York
|
+$101K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$2.95M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.31M |
| 3 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
-$869K |
| 4 |
EP
Eversept Partners
New York
|
-$515K |
| 5 |
FIA
FNY Investment Advisers
New York
|
-$482K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
JP Morgan Chase
New York
| – | -$247K | -62,475 | Closed |
|
27
Barclays
London,
United Kingdom
| – | -$185K | -49,900 | -100% |
|
|
OAM
28
Oxford Asset Management
Oxford,
United Kingdom
| – | -$179K | -45,078 | Closed |
|
|
LI
29
Leap Investments
Chicago,
Illinois
| – | -$138K | -34,918 | Closed |
|
30
Fidelity Investments
Boston,
Massachusetts
| – | -$33 | -9 | -53% |
|
|
PHK
31
Point72 Hong Kong
Hong Kong
| – | +$89 | +24 | New |
|
|
CSS
32
Cubist Systematic Strategies
Stamford,
Connecticut
| – | +$167 | +45 | New |
|
IFRX Hedge Fund Activity: Q1 2020 in Review
26 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in InflaRx (IFRX) for Q1 2020, worth a combined $19.2M — down 8.5% from $20.9M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new IFRX positions and 6 closed out — a net gain of 6 holders — while 3 added to existing stakes and 10 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $3.95M. The largest seller was Morgan Stanley, cutting an estimated $2.95M.
- 26 institutional investors held InflaRx (IFRX) as of Q1 2020, up from 20 in Q4 2019.
- Funds reported $19.2M of InflaRx stock for Q1 2020, down 8.5% quarter-over-quarter.
- 12 funds opened new InflaRx positions in Q1 2020 and 6 closed out, a net change of +6 holders.
- The largest InflaRx buyer in Q1 2020 was OrbiMed, an estimated $3.95M added.
- The largest InflaRx seller in Q1 2020 was Morgan Stanley, an estimated $2.95M sold.
Based on aggregated 13F filings for Q1 2020.